Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028028 · ClinicalTrials.gov registry record · Phase 2
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00028028: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00028028 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028028, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028028
The ClinicalTrials.gov registry entry for NCT00028028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00028028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028028 about?
NCT00028028 is a clinical study titled "CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
What is the current status of trial NCT00028028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2002-02.
What interventions are being tested in trial NCT00028028?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00028028?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.